Cancer Medicine - FOI Response Register

FoI Number
2023-482
Subject
Cancer Medicine
Date Received
09/11/2023
Request and Response

I have a freedom of information request regarding the treatment of certain types of cancer.  Could you please answer the following questions?

  1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
  • CAPOX (Capecitabine with Oxaliplatin)                           0
  • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)                  0
  • Lonsurf (Trifluridine - tipiracil)                                                         0
  • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)                                                         0
  • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)                0
  • Any other systemic anti-cancer therapy                           <5
  • Palliative care only                                                                           0
  1. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

The answer to all parts of Questions 2 and 3 is ZERO

  • Nivolumab monotherapy or combination with Ipilimumab
  • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  • Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  • Any other systemic anti-cancer therapy
  • Palliative care only       
  1. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:
  • Nivolumab monotherapy or combination with Ipilimumab
  • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  • Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  • Any other systemic anti-cancer therapy
  • Palliative care only